Antonio Pérez-Martínez

Rationale for combined therapies in severe-to-critical COVID-19 patients

A. Hmadcha, J. M. Sempere-Ortells, R. Goterris, 2023, Frontiers in Immunology.

Results of phase 2 randomized multi-center study to evaluate the safety and efficacy of infusion of memory T cells as adoptive therapy in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pneumonia and/or lymphopenia (RELEASE NCT04578210).

M. Díaz-Almirón, R. Goterris, R. de Paz, 2023, Cytotherapy.

BCG priming followed by a novel interleukin combination activates Natural Killer cells to selectively proliferate and become anti-tumour long-lived effectors

G. Esteso, C. Mestre-Durán, M. Valés-Gómez, 2024, Scientific reports.

Impact of disease burden and late loss of B cell aplasia on the risk of relapse after CD19 chimeric antigen receptor T Cell (Tisagenlecleucel) infusion in pediatric and young adult patients with relapse/refractory acute lymphoblastic leukemia: role of B-cell monitoring

J. Pérez-Simón, M. Torrebadell, T. Caballero-Velázquez, 2024, Frontiers in immunology.